PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Stock Rated “Moderate Buy” by Wall Street Analysts

by · The Markets Daily

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the five analysts that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, three have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $4.33.

A number of equities analysts have recently issued reports on PMVP shares. Weiss Ratings raised PMV Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, September 24th. LADENBURG THALM/SH SH assumed coverage on PMV Pharmaceuticals in a research note on Wednesday, July 8th. They set a “buy” rating and a $3.00 target price on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $5.00 target price on shares of PMV Pharmaceuticals in a research report on Friday, September 4th.

View Our Latest Stock Report on PMV Pharmaceuticals

PMV Pharmaceuticals Stock Performance

NASDAQ:PMVP opened at $1.78 on Tuesday. The company’s 50-day simple moving average is $1.33 and its 200-day simple moving average is $1.30. PMV Pharmaceuticals has a fifty-two week low of $1.02 and a fifty-two week high of $1.91. The stock has a market capitalization of $95.16 million, a P/E ratio of -1.25 and a beta of 1.36.

PMV Pharmaceuticals (NASDAQ:PMVP – Get Free Report) last posted its earnings results on Friday, August 14th. The company reported ($0.34) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.05. On average, research analysts forecast that PMV Pharmaceuticals will post -1.26 EPS for the current year.

Hedge Funds Weigh In On PMV Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. Cooper Haims Advisors LLC acquired a new position in PMV Pharmaceuticals during the 2nd quarter valued at approximately $52,000. Susquehanna International Group LLP acquired a new stake in shares of PMV Pharmaceuticals during the second quarter worth $50,000. Stonepine Capital Management LLC purchased a new stake in shares of PMV Pharmaceuticals during the second quarter valued at $718,355. Bank of America Corp DE purchased a new stake in shares of PMV Pharmaceuticals during the second quarter valued at $322,000. Finally, ADAR1 Capital Management LLC acquired a new position in shares of PMV Pharmaceuticals in the 2nd quarter valued at $269,000. Institutional investors and hedge funds own 90.20% of the company’s stock.

About PMV Pharmaceuticals

(Get Free Report)

PMV Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer. The company’s research centers on p53, a tumor-suppressor protein that is frequently altered in cancer, with the goal of developing therapies that restore the protein’s function in tumors containing specific p53 mutations.

PMV’s lead investigational product is rezatapopt (also known as PC14586), an orally administered small-molecule therapy designed to selectively reactivate the Y220C mutation of p53.

Featured Articles